Literature DB >> 17688236

Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.

Susan J Ramus1, Patricia A Harrington, Carole Pye, Richard A DiCioccio, Mark J Cox, Kim Garlinghouse-Jones, Ingrid Oakley-Girvan, Ian J Jacobs, Richard M Hardy, Alice S Whittemore, Bruce A J Ponder, M Steven Piver, Paul D P Pharoah, Simon A Gayther.   

Abstract

A total of 283 epithelial ovarian cancer families from the United Kingdom (UK) and the United States (US) were screened for coding sequence changes and large genomic alterations (rearrangements and deletions) in the BRCA1 and BRCA2 genes. Deleterious BRCA1 mutations were identified in 104 families (37%) and BRCA2 mutations in 25 families (9%). Of the 104 BRCA1 mutations, 12 were large genomic alterations; thus this type of change represented 12% of all BRCA1 mutations. Six families carried a previously described exon 13 duplication, known to be a UK founder mutation. The remaining six BRCA1 genomic alterations were previously unreported and comprised five deletions and an amplification of exon 15. One of the 25 BRCA2 mutations identified was a large genomic deletion of exons 19-20. The prevalence of BRCA1/2 mutations correlated with the extent of ovarian and breast cancer in families. Of 37 families containing more than two ovarian cancer cases and at least one breast cancer case with diagnosis at less than 60 years of age, 30 (81%) had a BRCA1/2 mutation. The mutation prevalence was appreciably less in families without breast cancer; mutations were found in only 38 out of 141 families (27%) containing two ovarian cancer cases only, and in 37 out of 59 families (63%) containing three or more ovarian cancer cases. These data indicate that BRCA1 and BRCA2 are the major susceptibility genes for ovarian cancer but that other susceptibility genes may exist. Finally, it is likely that these data will be of clinical importance for individuals in families with a history of epithelial ovarian cancer, in providing accurate estimates of their disease risks. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17688236     DOI: 10.1002/humu.20599

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  33 in total

Review 1.  The inherited genetics of ovarian and endometrial cancer.

Authors:  Simon A Gayther; Paul D P Pharoah
Journal:  Curr Opin Genet Dev       Date:  2010-04-24       Impact factor: 5.578

2.  Ovarian cancer risk associated with inherited inflammation-related variants.

Authors:  Kristin L White; Joellen M Schildkraut; Rachel T Palmieri; Edwin S Iversen; Andrew Berchuck; Robert A Vierkant; David N Rider; Bridget Charbonneau; Mine S Cicek; Rebecca Sutphen; Michael J Birrer; Paul P D Pharoah; Honglin Song; Jonathan Tyrer; Simon A Gayther; Susan J Ramus; Nicolas Wentzensen; Hannah P Yang; Montserrat Garcia-Closas; Catherine M Phelan; Julie M Cunningham; Brooke L Fridley; Thomas A Sellers; Ellen L Goode
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

3.  brca2 in zebrafish ovarian development, spermatogenesis, and tumorigenesis.

Authors:  Heather R Shive; Robert R West; Lisa J Embree; Mizuki Azuma; Raman Sood; Paul Liu; Dennis D Hickstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

4.  Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.

Authors:  Irene Konstanta; Florentia Fostira; Paraskevi Apostolou; Efstratios Stratikos; Despoina Kalfakakou; Andreas Pampanos; Panagoula Kollia; Christos Papadimitriou; Irene Konstantopoulou; Drakoulis Yannoukakos
Journal:  J Hum Genet       Date:  2018-08-15       Impact factor: 3.172

Review 5.  Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer.

Authors:  Lee P Shulman; Jeffrey S Dungan
Journal:  Cancer Treat Res       Date:  2010

6.  Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.

Authors:  Natalia Bogdanova; Alexandr V Togo; Magdalena Ratajska; Wojtek Kluźniak; Zalina Takhirova; Theresa Tarp; Darya Prokofyeva; Marina Bermisheva; Grigoriy A Yanus; Tatiana V Gorodnova; Anna P Sokolenko; Alina Kuźniacka; Amira Podolak; Maciej Stukan; Dominika Wokołorczyk; Jacek Gronwald; Danuta Vasilevska; Vilius Rudaitis; Ingo B Runnebaum; Matthias Dürst; Tjoung-Won Park-Simon; Peter Hillemanns; Natalia Antonenkova; Elza Khusnutdinova; Janusz Limon; Jan Lubinski; Cezary Cybulski; Evgeny Imyanitov; Thilo Dörk
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

7.  Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.

Authors:  Ava Kwong; L P Wong; H N Wong; F B F Law; E K O Ng; Y H Tang; W K Chan; D T K Suen; C Choi; L S Ho; K H Kwan; M Poon; T T Wong; K Chan; S W W Chan; M W L Ying; W C Chan; E S K Ma; J M Ford; D W West
Journal:  Hugo J       Date:  2010-04-10

8.  Risk of ovarian cancer and inherited variants in relapse-associated genes.

Authors:  Abraham Peedicayil; Robert A Vierkant; Lynn C Hartmann; Brooke L Fridley; Zachary S Fredericksen; Kristin L White; Elaine A Elliott; Catherine M Phelan; Ya-Yu Tsai; Andrew Berchuck; Edwin S Iversen; Fergus J Couch; Prema Peethamabaran; Melissa C Larson; Kimberly R Kalli; Matthew L Kosel; Vijayalakshmi Shridhar; David N Rider; Mark Liebow; Julie M Cunningham; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

Review 9.  Cancer models, genomic instability and somatic cellular Darwinian evolution.

Authors:  Mark P Little
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

Review 10.  The contribution of BRCA1 and BRCA2 to ovarian cancer.

Authors:  Susan J Ramus; Simon A Gayther
Journal:  Mol Oncol       Date:  2009-02-10       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.